Introduction
============

Prostate cancer (PCa) is the most common type of cancer in males and the second most common cause of male cancer-associated mortality in Western countries ([@b1-ol-0-0-11861]). It is necessary to stage PCa accurately prior to surgery, to ensure appropriate treatment options, clinical decisions and patient counseling are applied. PCa with adverse pathology tends to be more aggressive and harbors poorer prognosis ([@b1-ol-0-0-11861]). Adverse pathology is defined as ≥Grade Group 3 (GG 3)/Gleason score (GS) 4+3=7 radical prostatectomy (RP), extraprostatic extension (EPE), seminal vesicle invasion (SVI) or lymph node metastasis (LNM) ([@b2-ol-0-0-11861]). For patients with suspected EPE or SVI, surgical techniques may be modified to include, for example, a wider resection margin, enlarged lymph node dissection or nerve resection, in order to reduce the risk of positive surgical margin. In addition, for some patients with EPE or SVI, external beam radiation therapy may be a more appropriate choice compared with RP, which may have risks associated with incomplete resection ([@b3-ol-0-0-11861]). Multi-parametric magnetic resonance imaging (mpMRI) and MRI/ultrasound (US) fusion-targeted biopsy (TBx) are relatively new techniques for PCa detection. Studies have shown that TBx performs better in detecting clinically significant PCa (csPCa) compared with systematic biopsy (SB) alone ([@b2-ol-0-0-11861],[@b4-ol-0-0-11861]). Ahmed *et al* ([@b5-ol-0-0-11861]) found that mpMRI had a higher sensitivity compared with standard transrectal US (TRUS) in ruling out clinically insignificant diseases. Under prostate imaging reporting and data system (PI-RADS) version 2 ([@b4-ol-0-0-11861]), lesions receive an assessment PI-RADS score of 1--5, with higher scores being associated with a higher likelihood of clinically significant PCa (csPCa), which is when the cancer volume is ≥0.5 ml and/or GS ≥3+4 and/or stage ≥pT3 ([@b6-ol-0-0-11861]). Certain studies have demonstrated that the GS of PCa biopsy specimens is strongly associated with adverse pathology at the time of RP, biochemical recurrence and poor prognosis, with higher GS being associated with a worse treatment response ([@b5-ol-0-0-11861],[@b7-ol-0-0-11861]). Therefore, high-grade PCa is associated with a less favorable prognosis and impacts clinical decisions, such as determining the most appropriate treatment. Gleason pattern (GP) 4 is a heterogeneous group that is classified into several architectural patterns, including poorly formed, cribriform and fused glands, by the International Society of Urological Pathology (ISUP) ([@b8-ol-0-0-11861]). Compared with tumors with a non-cribriform pattern 4 (poorly-formed and fused glands), tumors with positive cribriform morphology are associated with a higher likelihood of EPE and metastasis ([@b9-ol-0-0-11861],[@b10-ol-0-0-11861]). Previous studies have suggested that cribriform morphology may be more aggressive and can optimize Gleason scoring ([@b6-ol-0-0-11861],[@b11-ol-0-0-11861]). In addition, studies have demonstrated that cribriform pattern in PCa is associated with an increased risk of biochemical recurrence and cancer-specific survival ([@b12-ol-0-0-11861],[@b13-ol-0-0-11861]).

Currently, several clinical nomograms have been developed, including GG and clinical factors, which can predict adverse pathology in PCa. However, to the best of our knowledge, no studies have incorporated pathological factors, such as cribriform morphology, into a nomogram for adverse pathology prediction. The aim of the present study was therefore to develop a novel nomogram incorporating biopsy cribriform morphology, imaging parameters and clinical factors to identify adverse pathology in PCa.

Materials and methods
=====================

### Study population

A total of 657 patients who underwent RP at Nanjing Drum Tower Hospital (Nanjing, China), due to histologically-confirmed PCa, between August 2016 and March 2019 were retrospectively included in the present study. The following patients were excluded: i) Patients with histologically-confirmed PCa from other medical institutions (n=169); ii) GP 5 on biopsy (n=27); iii) pure GP 3 on biopsy (n=142); iv) patients with a main lesion of \<PI-RADS 3 on MRI (n=6); and v) patients who had undergone previous treatment, including hormone therapy (n=82) and transurethral resection of the prostate (n=8; [Fig. 1](#f1-ol-0-0-11861){ref-type="fig"}). Finally, 223 patients who had undergone preoperative mpMRI, had GP 4 and absence of GP 5 on biopsy specimens (GS 3+4, GS 4+3, GS 4+4) were included in the present study. The median age was 69 years (age range, 50--84 years). The median age of adverse pathology-negative group and adverse pathology-positive group were used to determine age grouping. The study was approved by The Ethics Committee of the Nanjing Drum Tower Hospital (approval no. 2017-147-01) and all patients provided informed and signed consent.

### mpMRI examination and image evaluation

All patients underwent pelvic mpMRI using a 3.0-T MR scanner (Achieva 3.0 TTX; Philips Healthcare) using a 16-channel phased array coil, as previously described ([@b14-ol-0-0-11861]). Transverse/coronal/sagittal (18 slices; thickness, 3 mm/gap 0.5 mm; repetition time (TR), 3744 ms; time of echo (TE), 120 ms; number of signals acquired, 2; resolution, 1.49×1.51 mm) T2-weighted turbo spin-echo images were acquired. Diffusion weighted spin-echo echo-planar images (18 slices; thickness; 3 mm; intersection gap, 1 mm; TR, 925/TE, 41 ms; number of signals acquired, 1; resolution, 3×3 mm; b-factor, 0/800/1500 sec/mm^2^) were acquired. T1 high-resolution isotropic volume with fat suppression, following a 30 ml gadolinium injection was used for dynamic contrast-enhanced images (133 slices; thickness, 3 mm; no intersection gap; TR, 3.1/TE, 1.46 ms; number of signals acquired, 1; resolution, 1.49×1.51 mm; dynamic scan time, 00:06.9 min). All mpMRI imaging was reviewed by two radiologists with \>10 years of experience with prostate mpMRI, who were aware of the PCa diagnosis for all cases but blinded to the final pathology, including the GS. Regions of interest (ROI), defined as regions with an abnormal signal on mpMRI, were contoured and scored using PI-RADS ([@b6-ol-0-0-11861]). The maximum length, width and height of the suspected lesion on apparent-diffusion coefficient sequence were measured, and the prostate volume was calculated using the following formula: 0.52 × width × lenth × height'.

### Biopsy protocol and pathological assessment

All biopsies were conducted using the mpMRI-US image registration system (Esaote^®^ and RVS^®^) that provided real-time fusion of TRUS and mpMR images, in order to guide the biopsy needles transperineally. The biopsy started with TB, aiming at the center of suspicious lesions, using the free-hand transperineal ([@b7-ol-0-0-11861]) method by a senior urologist, and then standard systematic 12-core transperineal SB (blinded to the MRI target lesions) was conducted in all patients by another dedicated urologist. An 18-G automatic biopsy gun with a specimen size of 18 mm (Gallini Medical; [www.gallinimedical.com](www.gallinimedical.com)) was used to obtain biopsy cores ([@b14-ol-0-0-11861]). Biopsy cores were graded by two genitourinary pathologists at Nanjing Drum Tower Hospital (Nanjing, China), in accordance with the ISUP guidelines ([@b15-ol-0-0-11861]). GG is based on the highest GG on TB and SB pathological outcomes. The GGs, used in parallel to the modified Gleason grading system, translate GSs in five distinct risk categories, where GG 1 is defined as GS 6, GG 2 as GS 3 + 4 = 7, GG 3 as GS 4 + 3 = 7, GG 4 as GS 8 and GG 5 as GS 9/10 ([@b16-ol-0-0-11861]). Cribriform morphology on biopsy was identified by genitourinary pathologists at Nanjing Drum Tower Hospital.

### Whole-mount pathological evaluation

Following robotic-assisted RP, whole-mount tissues were fixed using 10% formalin, embedded in paraffin, microtome-cut into 4--5 mm slices and hematoxylin & eosin-stained, according to the standard protocol ([@b17-ol-0-0-11861]). All whole mount histology slides were subsequently digitalized using a scanning system (NanoZoomer Digital Pathology System; Hamamatsu Photonics K.K.). All pathological images were interpreted by the genitourinary pathologists. To identify pathological ROI, tumor lesions were contoured, and corresponding GS were assigned. Cribriform morphology was identified by the genitourinary pathologists at Nanjing Drum Tower Hospital. For primary analyses, adverse pathology was defined as ≥GG 3/GS 4+3=7 RP, EPE, SVI or LNM ([@b2-ol-0-0-11861]).

### Statistical analysis

All patient demographics, cribriform morphology on biopsy, RP pathological results and MRI findings were analyzed descriptively. Patients with or without adverse pathological characteristics, cribriform morphology on biopsy, biopsy GG and PI-RADS score were shown. Mann-Whitney U tests were used for continuous variables and the χ^2^ test for categorical variables. Univariate and multivariate logistic regression analyses were performed to determine significant predictors of adverse pathology for nomogram development. The performance of the novel nomogram in predicting adverse pathology was assessed by receiver operating characteristics (ROC) curves, area under the curve (AUC) values and 95% confidence interval (CI), sensitivity and specificity were calculated. The extent of over- or underestimation of predicted probabilities relative to observed probabilities of adverse pathology was explored graphically using calibration plots, which were internally validated using bootstrapping with 1,000 iterations. Decision curve analysis (DCA) identified the optimal approach for adverse pathology detection by comparing the net benefit of each factor across different threshold probabilities. Statistical analyses were performed using R version 3.5.2 ([@b8-ol-0-0-11861]) (packages rms, pROC and ggplot 2) and R studio software \[version 1.1.383; ([@b9-ol-0-0-11861])\]. DCA was performed using the DCA package ([@b18-ol-0-0-11861]). All descriptive analyses were performed using SPSS version 22.0 software (IBM Corp). For tests of all variables, P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

A total of 223 PCa patients, who underwent preoperative mpMRI, had GP 4 and absence of GP 5 (GS 3+4, GS 4+3, GS 4+4) in biopsy specimens, were retrospectively enrolled in the present study. [Table I](#tI-ol-0-0-11861){ref-type="table"} includes the characteristics of all enrolled patients with PCa. The median age was 69 years, and the median PSA level was 13.16 ng/ml.

### Characteristics of patients with or without adverse pathology

The demographics, biopsy GG, PI-RADS score and cribriform architecture on biopsy with and without adverse pathology are shown in [Table II](#tII-ol-0-0-11861){ref-type="table"}. The patients harboring adverse pathology were older compared with those who did not (71.00 vs. 68.00 years; P=0.04). The PSA level of patients with adverse pathology was higher compared with patients without (14.59 vs. 10.20 ng/ml; P\<0.01). Compared with patients without adverse pathology, the maximum lesion diameter was longer in the MRI of patients with adverse pathology (1.90 vs. 1.20 cm, P\<0.01). The contribution of PI-RADS score and GG on biopsy was also observed. For PI-RADS score 3 PCa, the detection rates of adverse pathology were 7/23 (30.4%). In contrast, PI-RADS score 4 PCa was more likely to have adverse pathology \[41/70 (58.6%) vs. 7/23 (30.4%) P=0.02\]. However, the detection rates of adverse pathology for PI-RADS score 5 PCa were the highest \[110/130 (84.6%) vs. 7/23 (30.4%); P\<0.01\]. The present study demonstrated that a higher preoperative GG on biopsy was associated with a higher likelihood of adverse pathology in PCa. The prediction rates of biopsy GG 2, GG 3, GG 4 were 24/59 (40.7%), 57/79 (72.2%) and 77/85 (90.6%), respectively. For cribriform morphology-positive PCa, the rates of adverse pathology detection were 60/68 (88.2%). By contrast, cribriform morphology-negative PCa was associated with a decreased likelihood of adverse pathology \[98/155 (63.2%) vs. 60/68 (88.2%); P\<0.01\]. Representative radiopathological matching of cribriform morphology-positive lesion on biopsy and RP are shown in [Fig. 2](#f2-ol-0-0-11861){ref-type="fig"}.

### Univariate and multivariate logistic regression analyses for the detection of adverse pathology

In univariate logistic regression analysis for the prediction of adverse pathology in PCa, prostate specific antigen density (PSAD) (P\<0.01), maximum lesion diameter on MRI (P\<0.01), cribriform morphology on biopsy (P\<0.01), biopsy GG (P\<0.01) and PI-RADS score (P\<0.01) were significant factors. In multivariate logistic regression analysis for the prediction of adverse pathology, PSAD (P=0.03), cribriform morphology (P=0.02), biopsy GG (P\<0.01) and PI-RADS score (P\<0.01) were significant factors and were included in the nomogram construction ([Table III](#tIII-ol-0-0-11861){ref-type="table"}; [Fig. 3](#f3-ol-0-0-11861){ref-type="fig"}). The AUC of the novel nomogram was 0.88 (95% CI, 0.84--0.91), with a high specificity (0.91) and moderate sensitivity (0.72; [Fig. 4](#f4-ol-0-0-11861){ref-type="fig"}). Bootstrapped calibration plots of the nomogram ([Fig. 5](#f5-ol-0-0-11861){ref-type="fig"}) demonstrated that there were no significant deviations of the predicted risk from the observed risk of adverse pathology in PCa over the entire range (mean absolute error=0.017). In DCA, compared with PSAD, cribriform morphology on biopsy, biopsy GG, PI-RADS score, the nomogram had a higher net benefit for the prediction of adverse pathology ([Fig. 6](#f6-ol-0-0-11861){ref-type="fig"}).

Discussion
==========

In the present study, a novel nomogram incorporating PSAD, PI-RADS score, cribriform morphology on biopsy and biopsy GG was developed, and showed a good prediction performance for PCa harboring adverse pathology.

Prediction models that combine clinical stage, serum PSA level and Gleason grade in biopsy specimens are commonly used in clinical practice to predict the pathological stage of PCa. The Partin ([@b19-ol-0-0-11861]) and Memorial Sloan Kettering Cancer Center pre-RP ([@b20-ol-0-0-11861]) nomograms are examples of predicted models widely used for preoperative decision-making. However, imaging parameters and pathological factors, such as mpMRI and cribriform pattern, are not included in the nomogram, which are generally recognized as valuable factors for improved detection of PCa harboring adverse pathology. Rayn *et al* ([@b21-ol-0-0-11861]) showed that MRI, alone or combined with standard clinical nomograms, provides additional predictive value of adverse pathology at the time of RP. Although MRI was incorporated, the Rayn *et al* nomogram had certain limitations. First, PI-RADS version 2 (v2) was not used to evaluate the effect of MRI uniformly. PI-RADS v2 is widely accepted by peer experts for MRI accessing and clinical practice as guidance ([@b6-ol-0-0-11861]). It was observed in the present study that a higher PI-RADS score was associated with an increased likelihood of adverse pathology. Junker *et al* ([@b22-ol-0-0-11861]), reported that PI-RADS 4 and PI-RADS 5 were associated with high-grade PCa. Lim *et al* ([@b23-ol-0-0-11861]), showed that PI-RADS 5 was associated with a higher GSs and EPE compared with PI-RADS 4. Secondly, pathological factors were not included in the nomogram of Rayn *et al*. The present study incorporated pathological factors, including cribriform morphology on biopsy, into the nomogram, and observed a favorable prediction performance for adverse pathology.

Sarbay *et al* ([@b24-ol-0-0-11861]), reported that cribriform morphology on prostate biopsy was associated with an increased likelihood of positive surgical margins and extraprostatic extension at the time of RP. Another study showed that perineural invasion on biopsy was associated with adverse pathology at the time of RP; however, perineural invasion was inferior to cribriform pattern in predicting non-organ-confined disease at the time of RP ([@b25-ol-0-0-11861]). Over the past few years, several studies have shown that cribriform-positive PCa is associated with an increased likelihood of lymph node invasion and distant metastasis ([@b10-ol-0-0-11861],[@b26-ol-0-0-11861]). The present study also demonstrated that the presence of cribriform morphology on biopsy was associated with an increased risk of adverse pathology in PCa compared with RP pathological outcomes. Therefore, cribriform morphology on biopsy, which was incorporated into the present nomogram, is a significant factor for predicting PCa harboring adverse pathology. Although not yet practiced clinically, and given that cribriform morphology has not been extensively studied, reporting cribriform morphology on prostate biopsies is strongly encouraged by some experts. Suggestions for accommodating the presence of cribriform cancer into the 2014 GG scheme have been made ([@b6-ol-0-0-11861]). The present team has recently been trying to encourage pathologists to report cribriform morphology on prostate biopsies at Nanjing Drum Tower Hospital. In addition, a higher GG was found to be associated with an increased risk of adverse pathology in PCa compared with RP pathological results. Aminsharifi *et al* ([@b27-ol-0-0-11861]), showed that a higher preoperative biopsy GG is linked to a higher risk of adverse histopathological findings at the time of RP. Hence, for a patient with a high biopsy GG and positive cribriform morphology on biopsy, a careful evaluation should be conducted to ensure suitable treatment strategies are followed.

A strength of the present study was that cribriform morphology on prostate biopsy was incorporated into the nomogram. To the best of our knowledge, the present study is the first to incorporate pathological factors into the nomogram predicting adverse pathology in PCa. In addition, the final pathological results were based on whole-mount pathological analyses. However, the present study had certain limitations. Firstly, it was a retrospective study and therefore has the bias associated with this type of study. Secondly, only a limited number of patients fitted the inclusion criteria. Thirdly, the final pathology was used as a reference standard, thus a selection bias is likely to have occurred, in that patients with lower-risk disease are less likely to have RP and negative- or low-risk patients were not included. Nonetheless, the final RP specimen is the most accurate reference standard to determine the presence or absence of PCa harboring adverse pathology. Fourthly, according to the study aim, only patients with a GP of 4 and without pure GP 3 and GP 5 were enrolled in the study, which might restrict clinical application to the general population. However, Stroup *et al* ([@b28-ol-0-0-11861]) showed that any GP 5 on biopsy, which indicated a poor prognosis, is associated with a higher likelihood of metastasis and PCa-specific mortality and adverse outcomes. In addition, an increasing number of studies have demonstrated that pure GP 3 diseases on biopsy have negligible PCa-specific mortality ([@b29-ol-0-0-11861]) and metastasis ([@b30-ol-0-0-11861]). Therefore, the inclusion criteria for the present study were considered suitable and in line with clinical practice. Finally, because of short postoperative time, follow-up of patients to evaluate the predictive value of the nomogram in biochemical recurrence was not conducted. Therefore, future studies should be conducted to verify the results of the present imaging models.

The present study found that a novel nomogram incorporating PSAD, PI-RADS score, cribriform morphology on biopsy and biopsy GG provided a significant predictive ability for PCa harboring adverse pathology at the time of RP. Urologists can use this nomogram to counsel patients regarding surgery techniques and future therapies and help them make significant management decisions. In future, the present nomogram should be validated in an independent cohort.
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![Flowchart detailing the exclusion criteria of the present study. RP, radical prostatectomy; PCa, prostate cancer; PI-RADS, Prostate Imaging Reporting and Data System; TURP, transurethral resection of the prostate.](ol-20-03-2797-g00){#f1-ol-0-0-11861}

![A representative case of prostate cancer harboring adverse pathology. A 67-year-old man with protein specific antigen density of 9.9 ng/ml, prostate volume of 23.90 ml. (A) T2-weighted image shows a significantly hypointense lesion in the left peripheral zone (red). (B) Diffusion weighted imaging with b1500 shows a high signal on the left peripheral zone (red). (C) Lesion was hypointense on apparent-diffusion coefficient map (red), MRI/ultrasound fusion-guided biopsy and systematic biopsy was conducted and showed the highest Gleason score 3+4 (Grade Group 2). All the finding results in a Prostate Imaging Reporting and Data System score 5. (D) MRI/ultrasound fusion-guided biopsy and systematic biopsy was conducted and showed Gleason score 3+4 with cribriform morphology. The magnification of the picture is at ×250 magnification. (E) Whole mount histology demonstrated that the lesion was a clinically significant with Gleason score 4+3=7, with extraprostatic extension. Magnification, ×100. (F) Representative cribriform morphology derived from whole mount histology. The magnification of the picture is 50 µm.](ol-20-03-2797-g01){#f2-ol-0-0-11861}

![Nomogram to predict adverse pathology in prostate cancer including PI-RADS score, PSAD, cribriform morphology on biopsy and biopsy GG. PI-RADS, Prostate Imaging Reporting and Data System; PSAD, protein specific antigen density; GG, grade group.](ol-20-03-2797-g02){#f3-ol-0-0-11861}

![Receiver operating characteristic curve analysis for the performance of adverse pathology nomogram. AUC, area under the curve; CI, confidence interval.](ol-20-03-2797-g03){#f4-ol-0-0-11861}

![Calibration plots for the nomogram to predict adverse pathology in prostate cancer.](ol-20-03-2797-g04){#f5-ol-0-0-11861}

![Net decision curve analysis demonstrating the benefit of adverse pathology nomogram for prediction of adverse pathology in prostate cancer. PI-RADS, Prostate Imaging Reporting and Data System; GG, grade group; PSAD, protein specific antigen density.](ol-20-03-2797-g05){#f6-ol-0-0-11861}

###### 

Characteristics of all 223 patients with prostate cancer included in the present study.

  Characteristics                          Value
  ---------------------------------------- ----------------------
  Age, years (range)                       69 (50--84)
  PSA level, ng/ml (range)                 13.16 (4.02--110.48)
  Prostate volume, ml (range)              30.1 (8.20--119.00)
  PSAD, ng/ml (range)                      0.45 (0.05--3.44)
  Maximum diameter on                      1.70 (0.20--4.60)
  MRI, cm (range)                          
  mpMRI findings, n (%)                    
    PI-RADS score 3                        23 (10.3)
    PI-RADS score 4                        70 (31.4)
    PI-RADS score 5                        130 (58.3)
    Suspected extraprostatic extension     113 (50.7)
    Suspected seminal vesicle invasion     20 (9.0)
    Suspected lymph node invasion            6 (2.7)
  Grade Group on RP, n (%)                 
    1                                      2 (0.9)
    2                                      97 (43.5)
    3                                      89 (39.9)
    4                                      17 (7.6)
    5                                      18 (8.1)
  pT stage, n (%)                          
    2                                      93 (41.7)
    3a                                     97 (43.5)
    3b                                     31 (13.9)
    4                                      2 (0.9)
  pN stage, n (%)                          
    0                                      208 (0.93)
    1                                        15 (0.07)
  Cribriform morphology on biopsy, n (%)   
    Negative                               155 (69.5)
    Positive                                 68 (30.5)

PSA, prostate specific antigen; PSAD, prostate specific antigen density; Maximum diameter, maximum diameter of lesion on MRI; RP, radical prostatectomy; mpMRI, multiparametric magnetic resonance imaging; PI-RADS, Prostate Imaging Reporting and Data System; pN, pathological N stage; pT, pathological T stage.

###### 

Characteristics of patients with or without adverse pathology in the study (n=158 and 64, respectively).

                                           Adverse pathology                           
  ---------------------------------------- -------------------- ---------------------- ------------------------------------------------------
  Age, years (range)                       68 (52--81)          71 (50--84)              0.04
  PSA level, ng/ml (range)                 10.20 (4.02--100)    14.59 (4.00--110.48)   \<0.01
  Prostate volume, ml (range)              27.9 (15.8--85.90)   33.2 (8.20--119.00)      0.17
  PSAD, ng/ml (range)                      0.34 (0.05--2.83)    0.49 (0.05--3.44)      \<0.01
  Maximum diameter on MRI, cm (range)      1.20 (0.20--3.80)    1.90 (0.50--4.60)      \<0.01
  PI-RADS score, n (%)                                                                 
    3                                      16 (69.6)            7 (30.4)               
    4                                      29 (41.4)            41 (58.6)              0.02^[a](#tfn3-ol-0-0-11861){ref-type="table-fn"}^
    5                                      20 (15.4)            110 (84.6)             \<0.01^[b](#tfn4-ol-0-0-11861){ref-type="table-fn"}^
  Grade Group on biopsy, n (%)                                                         
    2                                      35 (59.3)            24 (40.7)              
    3                                      22 (27.8)            57 (72.2)              \<0.01^[c](#tfn5-ol-0-0-11861){ref-type="table-fn"}^
    4                                      8 (9.4)              77 (90.6)              \<0.01^[d](#tfn6-ol-0-0-11861){ref-type="table-fn"}^
  Cribriform morphology on biopsy, n (%)                                               
    Negative                               57 (36.8)            98 (63.2)              \<0.01^[e](#tfn7-ol-0-0-11861){ref-type="table-fn"}^
    Positive                               8 (11.8)             60 (88.2)              

PSA, prostate specific antigen; PSAD, prostate specific antigen density; Maximum diameter, maximum diameter of lesion on MRI; PI-RADS, Prostate Imaging Reporting and Data System.

PI-RADS score 4 vs. PI-RADS score 3

PI-RADS score 5 vs. PI-RADS score 3

Grade Group 3 vs. Grade Group 2

Grade Group 4 vs. Grade Group 2

Cribriform morphology positive vs. negative.

###### 

Univariate and multivariate logistic regression analyses for the detection of adverse pathology in prostate cancer.

                                              Univariate logistic regression   Multivariate logistic regression                        
  ------------------------------------------- -------------------------------- ---------------------------------- -------------------- --------
  Age, per 5 years                            1.09 (0.94--1.26)                  0.24                             NA                   NA
  PSAD, interquartile OR                      2.26 (1.81--2.81)                  \<0.01                           1.40 (1.03--1.92)    0.03
  Maximum diameter on MRI, interquartile OR   2.30 (1.84--2.87)                  \<0.01                           0.85 (0.54--1.32)    0.49
  Cribriform morphology on biopsy                                                                                                      
    No                                        1 (Ref)                                                             1 (Ref)              
    Yes                                       20.70 (6.34--67.55)              \<0.01                             4.45 (1.24--15.90)   0.02
  Grade Group on biopsy                                                                                                                
    2                                         1 (Ref)                                                             1 (Ref)              
    3                                         3.14 (1.60--6.17)                \<0.01                             2.05 (0.97--4.36)    \<0.01
    4                                         9.00 (4.67--17.35)               \<0.01                             4.39 (2.11--9.17)    \<0.01
  PI-RADS score                                                                                                                        
    3                                         1 (Ref)                                                             1 (Ref)              
    4                                         4.53 (2.12--9.69)                \<0.01                             2.99 (1.27--7.07)    \<0.01
    5                                         21.77 (10.03--47.24)             \<0.01                             8.48 (2.47--29.14)   \<0.01

PSAD, prostate specific antigen density; Maximum diameter, maximum diameter of lesion on MRI; OR, odds ratio; CI, confidence interval; PI-RADS, Prostate Imaging Reporting and Data System; NA, not applicable; Ref, reference.
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